LYLiping Yang

Liping Yang

*This is an algorithmically generated author record based on publicly available information.

Liping Yang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Aijuan Xie

    1 shared publication
  • Ranran Wang

    1 shared publication
  • Ruokun Yi

    Collaborative Innovation Center for Child Nutrition and Health Development, Chongqing Engineering Research Center of Functional Food, Chongqing Engineering Laboratory for Research and Development of Functional Food, Chongqing University of Education, Chongqing 400067, China

    1 shared publication
  • Xin Zhao

    Collaborative Innovation Center for Child Nutrition and Health Development, Chongqing Engineering Research Center of Functional Food, Chongqing Engineering Laboratory for Research and Development of Functional Food, Chongqing University of Education, Chongqing, China

    1 shared publication
  • Yongpeng He

    NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China

    1 shared publication
  • Zhaofeng Tian

    Department of Laboratory Diagnostics, Changhai Hospital Second Military Medical University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Limosilactobacillus fermentum XY18 Relieves CCl 4 ‐Induced Acute Liver Injury in Mice by Antioxidant and Anti‐Inflammatory

    by Ranran Wang, Liping Yang, Aijuan Xie, Ruokun Yi, Yongpeng He, Xin Zhao, Zhaofeng Tian

    This study investigated whether Limosilactobacillus fermentum XY18 (LF‐XY18) prevents carbon tetrachloride (CCl 4 )‐induced mice acute liver injury (ALI) by alleviating oxidative stress and inflammation. LF‐XY18 reduced liver weight, improved injury indices, and alleviated histological abnormalities in mice. LF‐XY18 significantly reduced serum alanine triglycerides (TG), aspartate aminotransferase (AST), total cholesterol (TC), and aminotransferase (ALT) levels and reduced the myeloperoxidase (MPO) and malondialdehyde (MDA) concentrations in both serum and liver tissues, while increasing glutathione (GSH) and superoxide dismutase (SOD) levels in these compartments. Moreover, LF‐XY18 activated the nuclear factor‐erythroid‐2‐related‐factor‐2 (Nrf2) antioxidant pathway, upregulating heme oxygenase‐1 (HO‐1), copper‐zinc superoxide dismutase (Cu/Zn‐SOD), manganese‐superoxide dismutase (Mn‐SOD), and glutathione peroxidase (GSH‐Px). Simultaneously, LF‐XY18 modulated the nuclear factor κ‐light‐chain‐enhancer of activated B cells (NF‐κB)‐mediated inflammatory responses, restoring the NF‐κB, B‐cell inhibitor‐α (IκB‐α), neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS), inducible NOS (iNOS), and cyclooxygenase‐2 (COX‐2) expressions. LF‐XY18 dose‐dependently ameliorated CCl 4 ‐induced ALI through oxidative stress and inflammation suppression, demonstrating probiotic properties suitable for development as hepatoprotective dietary supplements.